Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 64

Results For "minister"

980 News Found

PIB: Pharmaceutical industry in Maharashtra
Policy | August 03, 2022

PIB: Pharmaceutical industry in Maharashtra

The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.


PIB: Pharma companies manufacturing generic medicine
Policy | August 03, 2022

PIB: Pharma companies manufacturing generic medicine

Under the PMBJP, till 30.06.2022, 8742 PMBJKs have been opened across the country including Government Hospitals and Government premises.


PIB: India imported Rs. 35,249 crore worth APIs and Bulk drugs in 2021-22.
Policy | August 03, 2022

PIB: India imported Rs. 35,249 crore worth APIs and Bulk drugs in 2021-22.

India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.


Bulk Drug Park in the country :PIB
Policy | July 27, 2022

Bulk Drug Park in the country :PIB

The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park


Pharmaceuticals industry under Atmanirbhar Bharat programme
Policy | July 27, 2022

Pharmaceuticals industry under Atmanirbhar Bharat programme

India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.


Funds for R&D in drug discovery and manufacturing :PIB
Policy | July 26, 2022

Funds for R&D in drug discovery and manufacturing :PIB

An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.


India crosses ‘200 Crore’ COVID-19 vaccinations
News | July 18, 2022

India crosses ‘200 Crore’ COVID-19 vaccinations

PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive


Strand Life Sciences presents report on ‘Genomic Surveillance of SARS-CoV-2’
News | July 18, 2022

Strand Life Sciences presents report on ‘Genomic Surveillance of SARS-CoV-2’

Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru


India’s first homegrown mRNA COVID-19 vaccine likely to have low market penetration, says GlobalData
News | July 11, 2022

India’s first homegrown mRNA COVID-19 vaccine likely to have low market penetration, says GlobalData

Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small